Growing Pains for Generic Drugs: OGD Gains Respect, But Loses Geba
This article was originally published in RPM Report
FDA’s Office of Generic Drugs was at the start of a turnaround: $299 million in new user fees to clear a big ANDA backlog and fund overseas inspections, an elevated status within the Center for Drugs and a brand-new director to steer the ship. But there have been some bumps in GDUFA implementation, and OGD’s new director, Gregory Geba, has abruptly left the agency. What next for FDA’s generic drug oversight?
You may also be interested in...
The reauthorization of the Generic Drug User Fee Act isn’t going to be as straightforward as the PDUFA process has been for the past two decades. Instead, expect a replay of the first medical device fee renegotiation – with plenty of threats from industry to walk away from the program altogether, likely intended to end up with the best possible deal.
It took a while, but the Office of Pharmaceutical Quality is finally ready to begin operations. Biopharma companies should recognize the declaration of FDA’s priorities, and respond accordingly.
FDA’s proposed Office of Pharmaceutical Quality will be initially headed by CDER Director Janet Woodcock. OPQ would hold responsibility over the manufacturing quality of a drug or biologics throughout a product’s lifecycle; eight offices will oversee activities from policy development to surveillance.